Key result
Slower dose escalation of quinapril (every 6 weeks) provided higher blood pressure control rates than rapid escalation (68.0% vs 62.3%, P=0.02) and fewer serious adverse events.
Why the study?
Does a fast drug dose escalation of quinapril compared to a slow dose escalation improve blood pressure control and reduce adverse events in patients with stage 1 to 2 hypertension?
RCT (n=2,935)
parallel-group
Yes
Does a fast drug dose escalation of quinapril compared to a slow dose escalation improve blood pressure control and reduce adverse events in patients with stage 1 to 2 hypertension?
Absolute Event Rate: 68% vs 62.3%
p-value: p=0.02
Slower dose escalation of quinapril (every 6 weeks) achieves better blood pressure control and fewer serious adverse events compared to rapid escalation (every 2 weeks) in patients with stage 1-2 hypertension.
No takes yet. Share an insight, caveat, or question.
Supports slower quinapril titration in hypertension; extends RCT evidence favoring gradual ACE inhibitor dosing.
John M. Flack (2000) conducted an RCT in Hypertension (n=2,935). Slow drug titration of quinapril (every 6 weeks) vs. Fast drug titration of quinapril (every 2 weeks) was evaluated on Blood pressure control to lower than 140/90 mm Hg at the third clinic visit (p=0.02). Slower dose escalation of quinapril (every 6 weeks) provided higher blood pressure control rates than rapid escalation (68.0% vs 62.3%, P=0.02) and fewer serious adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: